BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 21383694)

  • 1. Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer.
    Roberts CG; Millar EK; O'Toole SA; McNeil CM; Lehrbach GM; Pinese M; Tobelmann P; McCloy RA; Musgrove EA; Sutherland RL; Butt AJ
    Oncogene; 2011 Jul; 30(28):3186-97. PubMed ID: 21383694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
    Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response.
    van Agthoven T; Sieuwerts AM; Meijer D; Meijer-van Gelder ME; van Agthoven TL; Sarwari R; Sleijfer S; Foekens JA; Dorssers LC
    Endocr Relat Cancer; 2010 Mar; 17(1):215-30. PubMed ID: 19966015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
    Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
    Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels.
    Zhang GJ; Kimijima I; Onda M; Kanno M; Sato H; Watanabe T; Tsuchiya A; Abe R; Takenoshita S
    Clin Cancer Res; 1999 Oct; 5(10):2971-7. PubMed ID: 10537367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer.
    Kurebayashi J; Nukatsuka M; Sonoo H; Uchida J; Kiniwa M
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):219-25. PubMed ID: 19455332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC; Johnston SR; Smith IE; Dowsett M
    Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paradoxical regulation of Bcl-2 family proteins by 17beta-oestradiol in human breast cancer cells MCF-7.
    Leung LK; Wang TT
    Br J Cancer; 1999 Oct; 81(3):387-92. PubMed ID: 10507761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells.
    Vendrell JA; Ghayad S; Ben-Larbi S; Dumontet C; Mechti N; Cohen PA
    Oncogene; 2007 Jul; 26(32):4656-67. PubMed ID: 17297453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A possible regulatory role of 17beta-estradiol and tamoxifen on glyoxalase I and glyoxalase II genes expression in MCF7 and BT20 human breast cancer cells.
    Rulli A; Antognelli C; Prezzi E; Baldracchini F; Piva F; Giovannini E; Talesa V
    Breast Cancer Res Treat; 2006 Mar; 96(2):187-96. PubMed ID: 16319983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells.
    Frankel LB; Lykkesfeldt AE; Hansen JB; Stenvang J
    Breast Cancer Res Treat; 2007 Aug; 104(2):165-79. PubMed ID: 17061041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
    Lim YC; Desta Z; Flockhart DA; Skaar TC
    Cancer Chemother Pharmacol; 2005 May; 55(5):471-8. PubMed ID: 15685451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells.
    Cutrupi S; Reineri S; Panetto A; Grosso E; Caizzi L; Ricci L; Friard O; Agati S; Scatolini M; Chiorino G; Lykkesfeldt AE; De Bortoli M
    Oncogene; 2012 Oct; 31(40):4353-61. PubMed ID: 22249258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells.
    Kumar R; Mandal M; Lipton A; Harvey H; Thompson CB
    Clin Cancer Res; 1996 Jul; 2(7):1215-9. PubMed ID: 9816290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of two estrogen-responsive proteins by antiestrogens in R27, a tamoxifen-resistant clone of MCF7 cells.
    Vignon F; Lippman ME; Nawata H; Derocq D; Rochefort H
    Cancer Res; 1984 May; 44(5):2084-8. PubMed ID: 6713400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors.
    Marot D; Bieche I; Aumas C; Esselin S; Bouquet C; Vacher S; Lazennec G; Perricaudet M; Kuttenn F; Lidereau R; de Roux N
    Endocr Relat Cancer; 2007 Sep; 14(3):691-702. PubMed ID: 17914099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
    Osipo C; Gajdos C; Cheng D; Jordan VC
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen-induced activation of p21Waf1/Cip1 gene transcription is mediated by Early Growth Response-1 protein through the JNK and p38 MAP kinase/Elk-1 cascades in MDA-MB-361 breast carcinoma cells.
    Kim CG; Choi BH; Son SW; Yi SJ; Shin SY; Lee YH
    Cell Signal; 2007 Jun; 19(6):1290-300. PubMed ID: 17307334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.